Abstract-Uteroplacental acute atherosis (AA) is a pregnancy-specific arterial lesion resembling early stages of atherosclerosis. AA is frequent in preeclamptic pregnancies, which associate with increased long-term maternal risk of atherosclerotic cardiovascular disease. We hypothesized that AA in pregnant women associates with classical risk factors for cardiovascular disease, including hypertension, hyperlipidemia, glucose intolerance, elevated C-reactive protein, age, and body mass index. We included 237 women delivered by cesarean section (healthy pregnancies, n=94; preeclampsia, n=87; pregestational and gestational diabetes mellitus, n=39; diabetes mellitus with preeclampsia, n=17). They provided blood before delivery for biomarker analyses. AA was diagnosed by immunohistochemistry in uteroplacental (decidual) tissue collected after placental removal. Statistical analyses were performed with MannWhitney test. Levels of traditional cardiovascular markers were not associated with decidual AA within the groups of women with normotensive pregnancies, preeclampsia, diabetes mellitus, or diabetes mellitus superimposed with preeclampsia. However, the oldest patient age quartile (36-43 years old) with AA had significantly higher levels of LDL (low-density lipoprotein) and apolipoprotein B (both P<0.01) than women of the same age without AA. AA was associated with elevated median prepregnancy/early pregnancy systolic blood pressure (P=0.01) in the total cohort, but as preeclampsia was strongly associated with this finding (P<0.01), this was likely caused by a large proportion of preeclamptic pregnancies in the AA group (62.7%). Our findings demonstrate that dyslipidemia associated with cardiovascular risk is a feature of uteroplacental AA in older women, not of AA in pregnancy in general. (Hypertension.
C ardiovascular disease (CVD) is the most common cause of death worldwide and also causes most years of life lost, because of premature mortality. 1 It is the leading cause of death in women in the United States and Europe, the most frequent cause being of atherosclerotic origin. 2, 3 The risk of CVD is increased in women with a history of a new-onset hypertensive disorder of pregnancy, in particular, preeclampsia. 4 Consequently, in 2010 the American Heart Association included a history of hypertensive disorder of pregnancy as a major risk factor for CVD which should be included when screening women for CVD risk. 5 Other important CVD risk factors are the traditional risk factors originating from the Framingham studies: obesity, hyperlipidemia (cholesterol and lipoprotein), smoking, physical inactivity, insulin resistance (IR), 6 and adding to these: malnutrition, excessive alcohol intake, psychosocial factors, and abnormal levels of apolipoproteins. 7 Population-based studies have repeatedly shown a doseresponse association between preeclampsia and increased risk of CVD; the risk increasing by clinical severity and repeated preeclampsia. 4 Preeclampsia risk is also associated with established cardiovascular risk factors such as higher prepregnancy levels of blood lipids, 8 higher prepregnancy blood pressure (BP), and body mass index (BMI). 9 Coexistent fetal growth restriction, linked to severe placental dysfunction, also increases the CVD risk.
Current risk score strategies do not adequately target young women at increased risk for CVD. 10 As important risk factors for CVD are modifiable, and prevention of CVD is most likely to be effective when introduced at early stages of atherosclerosis, there is an urgent need to improve current CVD risk stratification for young women.
Acute atherosis (AA) is a lesion-specific to uteroplacental vessels and was originally described by Hertig et al 11 in 1945 . AA may appear in normotensive pregnancies, but appears at higher rates in pregnancies complicated by preeclampsia, reported prevalences varying considerably between 0.4% to 11% in normotensive controls, and as high as 50% in women with preeclampsia. [12] [13] [14] The traditional histological features were described as presence of subendothelial foam cells, fibrinoid necrosis of the artery media, and a perivascular lymphocyte infiltrate, similar to early atherosclerotic lesions. 15, 16 Although the underlying mechanisms for AA development are poorly understood, we have proposed that AA of the spiral arteries represent an accelerated form of vascular inflammation, resembling early stages of atherosclerosis, developing during the short time of pregnancy, arising from local excessive inflammation as the final common pathway. 16 As a first step to investigate associations between future maternal CVD and uteroplacental AA during pregnancy, we aimed in this article to establish whether uteroplacental AA coexists with established markers for CVD risk during pregnancy and at time of delivery.
Materials and Methods
Reasonable requests to access part of the anonymous data set can be sent to corresponding author, but access is restricted because of ongoing clinical follow-up, the sensitive nature of the data collected for this study, and the patient informed consents (and thereby ethical body approval). All procedures were in accordance with institutional guidelines.
Patient Recruitment
We recruited 237 singleton pregnant women before cesarean section to the Oslo Pregnancy Biobank study between January 2000 and December 2013 for a study of decidual AA. 12 Women with any chronic disease (with the exception of pregestational diabetes mellitus and 1 case with chronic hypertension), rupture of membranes, regular uterine contractions, severe infections, and a pregnancy with a fetal congenital malformation were excluded. The Regional Committee for Medical and Health Research Ethics of South East Norway approved the study, and all women provided written informed consent.
Preeclampsia was defined as new-onset hypertension (BP ≥140/90 mm Hg) and new-onset proteinuria (≥1+ on dipstick, or ≥30 mg/mmol protein/creatinine ratio) ≥20 weeks of pregnancy. 17 Pregestational and gestational diabetes mellitus (DM) were diagnosed according to World Health Organization guidelines. 18 Gestational week at delivery was according to dating by routine ultrasound screening at gestational week 17 to 20. Controls were women who remained normotensive and without glucosuria and without any positive oral glucose tolerance test during pregnancy.
Uteroplacental AA Diagnosis
Sampling and treatment of decidua basalis tissue (endometrium of pregnancy) during cesarean section and diagnosis of AA have previously been described 12 and are presented in the Materials and Methods in the online-only Data Supplement.
Blood Sampling and Risk Marker Analyses
Maternal blood serum was collected on the day of delivery before cesarean section as previously described, 19 from fasting (≥6 hours) women (except 2 nonfasting) and stored at −80°C until analysis.
Cholesterol, HDL (high-density lipoprotein), LDL (low-density lipoprotein), triglycerides, glucose, ApoA1 (apolipoprotein A1), ApoB (apolipoprotein B), and hsCRP (high-sensitive C-reactive protein) were all analyzed according to clinical routine by the Department of Clinical Biochemistry, Oslo University Hospital. Cholesterol, HDL, LDL, and triglycerides were measured by an enzymatic colorimetric method, glucose by an enzymatic method with hexokinase, and hsCRP by a particle-enhanced turbidometric method (Cobas 8000 c702, Roche Diagnostics). ApoA1 and ApoB were analyzed by an immunoturbidometric method (Cobas c501, Roche Diagnostics). Insulin was analyzed in-house by enzyme-linked immunosorbent assay (Mercodia, catalog number 10-1113). Biomarker results (LDL, triglycerides, glucose, and insulin) from the 2 nonfasting women were excluded from further analysis. In the absence of agreed global or Norwegian reference values for the pregnant population, we used reference values from a Danish pregnancy population. 20 To adjust for differences in gestational age at the time of blood sampling, biomarker z scores were calculated using the gestational age-specific reference ranges by Klajnbard et al. 20 Homeostatic model assessment-IR (HOMA-IR) scores were used to assess IR and calculated according to the HOMA2 model. 21 For some of the patients in the cohort, the insulin levels were below the lowest detectable standard value and assigned the lowest detectable value (3 mU/L).
As blood glucose is affected by glucocorticosteroids, 22 we excluded 10 women that had received bethamethasone (as fetal lung maturation) intramuscularly within the last 48 hours before blood sampling from the HOMA-IR analyses. The remaining 27 patients receiving bethamethasone >2 days from the blood sampling were included in HOMA-IR analyses.
BP and BMI
As most healthy women in Norway do not have their BP recorded before pregnancy and since BP levels change throughout even uncomplicated pregnancy, 23 we used the mean of all BPs recorded on the antenatal chart before 20th gestational week to calculate early pregnancy BP used in the risk scores. Serial outpatient BP (before 20th gestational week) were measured and recorded either by a doctor or a midwife as a part of the Norwegian Antenatal Care Program in primary care and prospectively documented in the national standard antenatal chart. 24 Further details about methods and devices used were not available to us. The inpatient hospital BP used to diagnose preeclampsia or normotensive pregnancy was based on repeated BP measurement with validated BP device (Dinamap Pro, 100VE, GE Medical Systems Information Technology, Inc Milwaukee, WI) following standard clinical routines.
If prepregnancy weight was not recorded in the national antenatal charts, maternal weight recorded during first trimester was used to calculate BMI and used as a proxy for prepregnancy BMI. Overweight was defined as BMI ≥25 kg/m 2 .
Statistics
Statistical analyses were performed with the Statistical Package for the Social Sciences (PASW Statistics 18). Differences in continuous variables between groups were tested by nonparametric MannWhitney tests. Kendall τ b test or binomial test was used to test for differences in dichotomous variables. Range was used as a measure of variance. A probability level of <0.05 was considered statistically significant.
Results
Demographic data, BPs, AA status, and circulating biomarkers for the total cohort and according to pregnancy complication are shown in Table 1 . Compared with nationwide Norwegian Birth Registry data, 25 our study population was of slightly higher age (32.0 versus 30.8 years) and with a somewhat higher proportion of pregnancies with a female fetus (51.9% versus 48.4%). The proportions of primiparous women (54.4% versus 42.6%), smokers (12.3% versus 4.7%), and women with prepregnancy or gestational DM (16.5% versus 5.8%) or preeclampsia (36.7% versus 2.7%) were as expected substantially higher in our selected study population as compared with national data. 25 The groups with preeclampsia, DM or DM+preeclampsia all had significantly higher median prepregnancy BMI, were more often overweight and more often delivered prematurely as compared with the controls. Women with preeclampsia and DM+preeclampsia were more often nulliparous compared with the controls. There were no significant differences in smoking habits in pregnancy (Table 1) .
Women with preeclampsia, DM, or DM+preeclampsia had higher systolic BP and diastolic BP in early pregnancy compared with controls ( Table 1 ). The rate of AA was significantly higher in women with preeclampsia (36.8%) compared with normotensive controls (10.6%, P<0.005), whereas the rates of AA in the group with DM and DM with superimposed preeclampsia were 10.3% and 29.4% respectively ( Table 1) . 12 With respect to the measured circulating biomarkers, only the group of women with preeclampsia differed from controls with significantly higher z-score transformed cholesterol, z-score transformed LDL, and higher triglycerides (absolute and z-score transformed [ Table 1 ; Table S1 in the online-only Data Supplement]). Demographic data, BPs, and circulating biomarkers for the total cohort and according to AA are presented in Table 2  and Table S2 .
In the total cohort, women with decidual AA had significantly lower median gestational age at delivery (Table 2) . Early pregnancy systolic BP was significantly higher in the group with AA compared with the group without AA ( Table 2) . Because of a higher fraction of preeclampsia patients in the AA group than in the no AA group, we also analyzed the diagnosis groups separately. As shown in Table S3 , there were no differences in these parameters according to AA status when analyzing for AA status within the groups of controls, preeclampsia, DM, or DM+preeclampsia.
Although IR is increased in pregnancy in general, and exaggerated in preeclamptic pregnancies, 26 we found no evidence of increased IR (as evaluated by the HOMA score) in women with AA as compared with women without AA (Table 2) , neither within the preeclampsia nor in the normotensive group, implicating that IR may not represent an important contribution to pregnancy AA.
As age, obesity, and smoking are acknowledged epidemiological risk factors of CVD, 6 we explored whether AA were differentially associated with CVD risk biomarkers in the oldest women in this cohort, in obese and in smoking women.
As shown in Table 3 and Table S4 , women in the oldest age quartile (36-44 years) with AA had significantly higher median levels (either in absolute or z-score levels) of cholesterol, LDL, and ApoB when compared with women without AA in the same age group. As shown in Table S5 , within the smaller group of women with preeclampsia within the same age range (36-44 years), the same variables were also significantly higher in women with AA compared with women without AA. In addition, within this subgroup (preeclampsia 36-44 years), women with AA had significantly higher levels of HDL (absolute and z-transformed) than women without AA. In pregnant control women within the same age range, only 3 women with AA had available data for circulating biomarkers. Hence, we could not compare women with and without AA, within this group.
Within the groups of smoking women and overweight women, CVD risk marker levels did not differ between women with and without AA ( Table 3 ). This was also the case within the group of overweight women with preeclampsia (Table  S5 ). There were too few smoking women with preeclampsia to analyze for differences between women with and without AA in that group. As shown in Table 1 , there were few cases with AA in the normotensive control group (n=10), DM (n=4), and DM+preeclampsia (n=5). Hence, we were unable to explore associations between CVD risk biomarkers and AA in the oldest age quartile, in overweight, and in smoking women within these groups.
Discussion
Our study is the first to explore whether the pregnancy-specific arterial lesion of uteroplacental AA is associated with classical CVD risk markers measured in pregnancy. In our pregnancy cohort, we did not find any association between these biomarkers and AA in the full cohort. However, we found that the oldest women (36-44 years) with AA had significantly increased levels of LDL and ApoB compared with pregnant women of same age without AA. A relative increase in LDL and ApoB levels is considered a key event in the development of early atherosclerotic lesions, and these lesions develop by age. 27 Our study could suggest a similar effect for the development of localized decidual AA in the oldest pregnant women. This association may be independent of a diagnosis of preeclampsia, as the presence of AA was associated with significantly higher serum levels of LDL, ApoB, and cholesterol in the oldest age quartile both for the whole study group, as well as for the preeclampsia subgroup.
We have previously suggested that AA represents an accelerated form of atherosclerosis with heterogeneous pathways, with excessive local inflammation as the final common pathway. 16, 28 Our finding of altered levels of CVD risk markers in the oldest part of the population supports this hypothesis, whereas other mechanisms for increased localized decidual tissue inflammation could be more important for foam cell generation and AA development in younger parts of the pregnant population.
Our cross-sectional study design is unable to determine the causation for the identified associations. The presence of uteroplacental AA in the decidual tissue can only be identified after delivery. We do not know when in pregnancy the decidual foam cell lesions appear, and hence also whether the hyperlipidemia in the older age groups is a phenomenon before AA development. Hyperlipidemia is a feature of a normal pregnancy and exaggerated in hypertensive pregnancies. 29 Consequently, it is unknown whether the lipid values observed in pregnancy are risk markers for future CVD, or whether they are merely associated with preeclampsia development.
AA was in our total cohort associated with a higher early pregnancy systolic BP, but as this difference was not seen neither in the subgroups of normotensive control women, women with preeclampsia, women with DM nor in women with preeclampsia+DM, this difference is likely because of the higher rate of preeclampsia in women with AA (as early pregnancy BPs, although being within the normotensive range by definition, tend to be higher in women developing preeclampsia than in women that remain normotensive through pregnancy). 30 In overweight women or women that reported any smoking during pregnancy, we could not detect any difference in CVD biomarkers according to AA status, but the numbers of smoking women in this study were small. Our study is strengthened by the uniform collection and handling of uteroplacental tissue samples and use of our validated histological criteria for AA diagnostics. 12 The vacuum suction method used collects more decidua basalis spiral arteries available for immunohistochemistry than the alternative placenta bed biopsy or maternal basal plate sampling methods. 14, 31 However, the patchy lesion pattern of AA and our serial slide sections of decidual tissue cannot exclude that some women were underdiagnosed with AA.
32
The selected population in our study, with a higher proportion of cases with preeclampsia and with more severe disease than what is the rate in the general population, makes the results more applicable to the female population with the highest risk for obstetric and thereby long-term cardiovascular health problems.
A challenge of our study was that reference ranges for many circulating biomarkers of CVD risk factors change throughout pregnancy. 20 To compensate for this, we prioritized analyses of circulating biomarkers where gestational agespecific reference values were available and analyzed z-score transformed values. However, as pregnancy-specific reference intervals may be wider than those used outside pregnancy, as well as not being specifically defined for noncases or case groups, the z-scored transformed values should be interpreted with caution.
The recently published smaller SPAR study (Spiral Artery Remodeling) included 3 cases of AA, evaluated by a different morphological method than our validated method, 33 not discriminating between myometrial or decidual artery findings. The SPAR study examined similar CVD risk markers as investigated in our study, but from maternal blood samples collected the day after cesarean section. Their finding of higher levels of triglycerides and LDL in the 3 patients with AA 33 was not confirmed in our study. The discrepancy may possibly be explained by our larger study population as well as by differing biopsy techniques of uteroplacental tissue and AA diagnosis criteria.
Stevens et al 34 examined whether decidual vasculopathy, a decidual lesion resembling AA, was associated with postpregnancy (2-74 months) CVD risk markers in women with preeclampsia in their index pregnancies. Except for identifying a higher diastolic BP in women who had decidual vasculopathy, the study found no association between CVD risk markers and AA postpartum, in line with our results from the time of delivery. However, the results from Stevens were obtained from postpartum women, and not from pregnant women as in our study. Biopsy techniques and diagnostic criteria for AA were also different, reducing the comparison validity.
Our present study supports that AA is related to hyperlipidemia and dyslipidemia in the older part of the pregnant population, which we speculate could also increase localized uteroplacental inflammation and subsequent generation of foam cells from macrophages. 35 We found no evidence of systemic inflammation or IR being associated to AA. Although preeclamptic women have increased risk for AA, hypertension is not a mandatory prerequisite for its development as AA is also present in normotensive pregnancies. We are further exploring our hypothesis of whether AA may represent a marker of women with the highest risk of future CVD 36 postpartum in a longitudinal follow-up of our Oslo Pregnancy Biobank cohort. If our hypothesis is confirmed, the presence of uteroplacental AA could represent a novel and clinically important risk stratification marker to target young women at highest risk for CVD. Such risk stratification would allow for more targeted preventive trials aiming at preventing or postponing a first and potential lethal cardiovascular event in parous women.
Perspectives
Uteroplacental AA was associated with traditional CVD biomarkers in the oldest part of our pregnant population, independent of a preeclampsia diagnosis. These women represent a young age group where biomarkers from outside pregnancy are of scarce value in predicting CVD risk. 37 As AA is more common in hypertensive disorders of pregnancy, it should be ascertained if AA shares further pathophysiological mechanisms with hypertensive disorder of pregnancy and atherosclerosis. Immunologic mechanisms are important in the development of both hypertensive disorder of pregnancy and atherosclerosis, and these are of particular interest for our future AA research.
If our hypothesis of AA representing a surrogate CVD risk marker is confirmed, it would represent a large clinical advantage for risk stratification and for targeted preventive efforts. Atherosclerosis at early stages is reversible, 38 and there is a large window of intervention opportunity between pregnancy in a young woman and her first and potential lethal cardiovascular event, occurring potentially 3 decades later.
